

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10575040	
	Filing Date		2006-12-06	
	First Named Inventor	Nozulak et al.		
	Art Unit	1625		
	Examiner Name	Chang, Celia C.		
Attorney Docket Number		VAND-0030-US		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/CC/	1	5158952		1992-10-27	Janssen et al.	
	2	4804663		1989-02-14	Kennis et al.	
/CC/	3	5364866		1994-11-15	Strupczewski et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

## U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/CC/	1	20040204401	A1	2004-10-14	Migaly	

If you wish to add additional U.S. Published Application citation information please click the Add button.

## FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/CC/	1	402644	EP	B1	1995-08-16	Strupczewski et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10575040
Filing Date	2006-12-06
First Named Inventor	Nozulak et al.
Art Unit	1625
Examiner Name	Chang, Celia C.
Attorney Docket Number	VAND-0030-US

/CC/	2	H03-63263	JP	A	1991-03-19	Hoechst-Roussel Pharma	<input type="checkbox"/>
/CC/	3	H09-511215	JP	A	1997-11-11	Hoechst-Marion-Roussel Pharma	<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

**NON-PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
/CC/	1	STRUPCZEWSKI, J.T. et al. "3-(Aryloxy) Alkylpiperidinyl-1,2-Benzosoxazoles as D2/5-HT2 Antagonists with Potential Atypical Antipsychotic Activity: Antipsychotic Profile of Iloperidone (HP 873), Journal of Medicinal Chemistry, Vol. 38, No. 7, pp. 1119-1131, 1995	<input type="checkbox"/>
	2	SUBRAMANIAN, N. et al., "Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone," Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26:553-560, 2002	<input type="checkbox"/>
	3	64 USPQ2d 1032 DECIDED 8/2002	<input type="checkbox"/>
	4	COREY E. J. et al., "A Stable and Easily Prepared Catalyst for the Enantioselective Reduction of Ketones. Applications to Multistep Syntheses", Journal of the American Chemical Society, Vol. 109, No. 25, pp. 7925-7926, 1987	<input type="checkbox"/>
	5	MUTLIB, A.E. et al., "Application of Liquid Chromatography/Mass Spectrometry in Accelerating the Identification of Human Liver Cytochrome P450 Isoforms Involved in the Metabolism of Iloperidone", The Journal of Pharmacology and Experimental Therapeutics, Vol. 286, No. 3 pp. 1285-1293.	<input type="checkbox"/>
	6	MUTLIB, A.E. et al., "Picogram determination of iloperidone in human plasma by solid-phase extraction and by high-performance liquid chromatography-selected-ion monitoring electrospray mass spectrometry", Journal of Chromatography B. 669, 1995, pp. 237-246	<input type="checkbox"/>
/CC/	7	MELTZER, H., "The Role of Serotonin an Antipsychotic Drug Action", Neuropsychopharmacology, Vol. 21, No. 2S, 1999	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10575040
Filing Date	2006-12-06
First Named Inventor	Nozulak et al.
Art Unit	1625
Examiner Name	Chang, Celia C.
Attorney Docket Number	VAND-0030-US

/CC/	8	WILLIAMS et al., "Importance of Drug Enantiomers in Clinical Pharmacology", Department of Clinical Pharmacology, St. Vincent's Hospital, Darlinghurst, Sydney, Drugs 30, 1985, pp 333-354	<input type="checkbox"/>
	9	KUNTZELMANN, " Functional characterization of the enantiomers of P88-8991 at the human $\alpha_2c$ adrenoceptor and the human dopamine D2A receptor", Novartis Pharma AG report, September 27, 2001, 8 pages	<input type="checkbox"/>
	10	NEUMANN, "The effect of the enantiomers of P88-8991 in ilperidone on spontaneous locomotion and amphetamine-induced locomotion in rats" Novartis Pharma AG report, September 27, 2001, 10 pages	<input type="checkbox"/>
	11	FURA, ABERRA, "Role of pharmacologically active metabolites in drug discovery and development", Drug Discovery Today, February 2006, 11(3/4): 133-142	<input type="checkbox"/>
	12	CLARKE, FRANK H., "Role of Drug Metabolism in Drug Research and Development: View of a Medicinal Chemist", Journal of Pharmaceutical Sciences, 1678	<input type="checkbox"/>
	13	BLUMER et al., "NVP-AES059-NX1 AND NVP-AES060-NX-1; Enantiomers of the P88 8991 metabolite of lloperidone: Receptor Affinity Profile (Short List)", Novartis Pharma AG report, January 28, 2001, 10 pages	<input type="checkbox"/>
	14	GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, March 16, 2006, 8 pages.	<input type="checkbox"/>
	15	GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, September 25, 2006, 7 pages	<input type="checkbox"/>
	16	GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, June 14, 2007, 8 pages.	<input type="checkbox"/>
	17	GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, March 6, 2008, 9 pages	<input type="checkbox"/>
/CC/	18	GRIMLER et al., Serial Number 10/488,128, 4-32076A, Office Action Communication, October 17, 2008, 13 pages	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10575040
Filing Date	2006-12-06
First Named Inventor	Nozulak et al.
Art Unit	1625
Examiner Name	Chang, Celia C.
Attorney Docket Number	VAND-0030-US

/CC/	19	GRIMLER et al, Serial Number 60/316,390, PV Application, August 31, 2001.	<input type="checkbox"/>
	20	GRIMLER et al., Serial Number 12/403,755 filed 03/13/2009, Attorney Docket No. VAND-0020-CON, Office Communication dated 05/05/2010, 12 pages.	<input type="checkbox"/>
	21	IMAMURA et al., "Interactions of pharmaceuticals with serum proteins", 1985, 1 page, CA 102:214444.	<input type="checkbox"/>
/CC/	22	OOKAWA et al., "Antitumor complexes and screening method thereof", 1994, 1 page, CA 120:62270.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature	/Celia Chang/	Date Considered	09/30/2010
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.